Kymera Therapeutics (NASDAQ: KYMR) has begun dosing in its BROADEN2 Phase 2b study of the oral STAT6 degrader KT‑621 in patients with moderate to severe atopic dermatitis. The randomized, double‑blind, placebo‑controlled trial will enroll roughly 200 participants over 16 weeks and will evaluate three dose levels of KT‑621, measuring percent change in the Eczema Area and Severity Index (EASI) at week 16 as the primary efficacy endpoint, along with safety and biomarker assessments.
The study design positions KT‑621 as a first‑in‑class oral degrader that could match the efficacy of injectable biologics while offering a convenient daily pill. The trial’s 52‑week open‑label extension will provide longer‑term safety data and help refine dosing for future indications. Kymera plans to report BROADEN2 data by mid‑2027, following the release of BroADen Phase 1b results in December 2025 and the launch of the BREADTH Phase 2b asthma trial in Q1 2026.
Kymera’s leadership highlighted the strategic importance of this milestone. Chief Medical Officer Jared Gollob said the dosing initiation “represents a major step in advancing our first‑in‑industry STAT6 degrader program and reflects the continued progress of our translational strategy, building a robust foundation for future development across multiple type‑2 diseases.” CEO Nello Mainolfi added that the company’s “impressive research, clinical, and regulatory progress this quarter” positions KT‑621 to potentially become an oral alternative to current biologic therapies for atopic dermatitis and other type‑2 inflammatory conditions.
The atopic dermatitis market, valued at over $10 billion globally, is dominated by topical treatments and injectable biologics such as dupilumab. KT‑621’s mechanism—catalytic degradation of STAT6—offers the prospect of biologics‑like efficacy with oral administration, potentially capturing a large share of the 130 million‑patient global addressable market for type‑2 diseases. Kymera’s pipeline also includes KT‑579 targeting IRF5 and plans for early‑phase studies in 2026, underscoring a broader strategy to expand its STAT6 platform beyond dermatology.
With a strong cash reserve and a projected runway into the second half of 2028, Kymera is positioned to sustain its clinical development program while pursuing regulatory milestones. The company’s focus on oral degraders aligns with industry trends toward small‑molecule alternatives to biologics, and the successful initiation of BROADEN2 strengthens its competitive positioning in a crowded therapeutic space.
revised_sentiment_rating
}
importance
high
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.